伊沙妥昔单抗单药及联合地塞米松治疗复发难治多发性骨髓瘤
这项2期研究评估伊沙妥昔单抗单药或联合地塞米松治疗复发难治多发性骨髓瘤。患者对免疫调节剂和蛋白酶体抑制剂难治或已接受≥3线含这两类药物的治疗。联合地塞米松提高了缓解率和生存结局,且未增加安全性风险。
要点
- 伊沙妥昔单抗联合地塞米松的ORR为43.6%,高于单药的23.9%。
- 联合组中位PFS为10.2个月,单药组为4.9个月。
- 两组≥3级感染发生率相似(22.0% vs 21.8%)。
核心结论
- 伊沙妥昔单抗联合地塞米松较单药提高了复发难治多发性骨髓瘤患者的缓解率和生存结局,且未对安全性产生不利影响。
研究设计与样本
- 2期研究,纳入164例复发难治多发性骨髓瘤患者,对免疫调节剂和蛋白酶体抑制剂难治或已接受≥3线含这两类药物的治疗。
- 患者接受伊沙妥昔单抗单药(20 mg/kg,第1周期每周一次,后续周期第1、15天)或联合地塞米松(40 mg/d,≥75岁者20 mg/d,每周一次)。
主要发现
- 中位无进展生存期和总生存期在单药组分别为4.9和18.9个月,联合组分别为10.2和17.3个月。
- 输注反应(多为1/2级)和血液学异常是最常见的不良事件;≥3级感染发生率两组相似(22.0%和21.8%)。
临床怎么用
- 对于复发难治多发性骨髓瘤患者,可考虑伊沙妥昔单抗联合地塞米松以提高缓解率和延长无进展生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase 2 study evaluated isatuximab as monotherapy or combined with dexamethasone in relapsed/refractory multiple myeloma (RRMM). Patients had RRMM refractory to an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) or had received ≥3 prior lines of therapy incorporating an IMiD and PI. Patients received isatuximab either as monotherapy (20 mg/kg on days 1, 8, 15, and 22 [once weekly] of cycle 1 followed by 20 mg/kg on days 1 and 15 of subsequent cycles; Isa group) or in combination with dexamethasone (40 mg/d [20 mg/d in patients aged ≥75 years] once weekly; Isa-dex group). Treated patients (N = 164) had received a median of 4 (range, 2-10) prior treatment lines. Patients received a median of 5 (1-24) and 7 (1-22) treatment cycles; at data cutoff, 13 (11.9%) of 109 and 15 (27.3%) of 55 patients remained on treatment in the Isa and Isa-dex arms, respectively. Overall response rate (primary efficacy end point) was 23.9% in the Isa arm and 43.6% in the Isa-dex arm (odds ratio, 0.405; 95% confidence interval, 0.192-0.859; P = .008). Median progression-free survival and overall survival were 4.9 and 18.9 months for Isa, and 10.2 and 17.3 months for Isa-dex. Infusion reactions (mostly grade 1/2) and hematologic abnormalities were the most common adverse events. There was a similar incidence of grade 3 or higher infections in both groups (22.0% and 21.8%). In conclusion, addition of dexamethasone to isatuximab increased response rates and survival outcomes with no detrimental effect on safety. This trial was registered at www.clinicaltrials.gov as #NCT01084252.
引用
- Dimopoulos M, Bringhen S, Anttila P, et al. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood. 2021. PMID: 33080623. doi:10.1182/blood.2020008209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。